Xeris Pharmaceuticals Inc. (NASDAQ: XERS): Hunting Genuine Value In Market Debris

    SBUX Stock
    SBUX Stock

    Sessa Capital IM LP recently announced the acquisition of new stake in Xeris Pharmaceuticals Inc. (NASDAQ:XERS). The institutional investor has increased its shareholding in the Healthcare company by 29.08% to 4.17 million shares with purchase of 0.94 million shares. This fresh investment now brings its stake to 9.27% valued currently at $11.93 million. In addition, BlackRock Fund Advisors raised its holdings by 0.41 million to 2.55 million shares.

    With over 6.12 million Xeris Pharmaceuticals Inc. (XERS) shares trading Friday and a closing price of $4.25 on the day, the dollar volume was approximately $26.01 million. The shares have shown a positive weekly performance of 2.16% and its price on 08/28/20 gained nearly 10.39%. Currently, there are 37.97M common shares owned by the public and among those 37.53M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for XERS have a consensus price objective of $11.00. The analysts have set the share’s price value over the next 12 months at a high of $14.00 and a low of $7.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Xeris Pharmaceuticals Inc. stock is 1.60 for the next 12 months. But an upside of 69.64% will see the stock hit the forecast high price target while mean target price for the stock is $11.00.

    Insiders at the company have transacted a total of 27 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, accounting for 526,069 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 47,301 shares.

    The top 3 mutual fund holders in Xeris Pharmaceuticals Inc. are Invesco Oppenheimer Global Opport, Vanguard Total Stock Market Index, and Meridian Small Cap Growth Fund. Invesco Oppenheimer Global Opport owns 2.0 million shares of the company’s stock, all valued at over $5.72 million. The company bought an additional 1.0 million shares recently to bring their total holdings to about 4.45% of the shares outstanding. Meridian Small Cap Growth Fund now owns shares totaling to 2.84% of the shares outstanding.

    Shares of Xeris Pharmaceuticals Inc. (NASDAQ: XERS) opened at $4.04, up $0.19 from a prior closing price of $3.85. However, the script later closed the day at $4.25, up 10.39%. The company’s stock has a 5-day price change of 2.16% and -16.83% over the past three months. XERS shares are trading -39.72% year to date (YTD), with the 12-month market performance down to -63.20% lower. It has a 12-month low price of $1.42 and touched a high of $12.29 over the same period. Currently, 6.12 million shares have been traded, compared to an average intraday trading volume of 3.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.29%, 25.04%, and -5.22% respectively.

    Institutional ownership of Xeris Pharmaceuticals Inc. (NASDAQ: XERS) shares accounts for 72.10% of the company’s 37.97M shares outstanding. Mutual fund holders own 26.51%, while other institutional holders and individual stakeholders account for 47.13% and 18.55% respectively.

    It has a market capitalization of $178.20M. The earnings-per-share (ttm) stands at -$3.97. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.99% over the week and 14.14% over the month.

    Analysts forecast that Xeris Pharmaceuticals Inc. (XERS) will achieve an EPS of -$0.56 for the current quarter, -$0.57 for the next quarter and -$1.72 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.73 while analysts give the company a high EPS estimate of -$0.47. Comparatively, EPS for the current quarter was -$1.22 a year ago. Earnings per share for the fiscal year are expected to decrease by -66.60%, and 33.80% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Xeris Pharmaceuticals Inc. (XERS) as a “Strong Buy” at a consensus score of 1.60. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”

    Looking at the support for the XERS, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on February 18, 2020, with the firm’s price target at $12. RBC Capital Mkts coverage for the Xeris Pharmaceuticals Inc. (XERS) stock in a research note released on July 16, 2018 offered a Outperform rating with a price target of $24. Leerink Partners was of a view on July 16, 2018 that the stock is Outperform, while Jefferies gave the stock Buy rating on July 16, 2018, issuing a price target of $23.


    Please enter your comment!
    Please enter your name here